therapeutics glp 1 activate Glucagon-like peptide-1 receptor: mechanisms and advances in therapy The multifaceted role of GLP-1

Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM

These included CT-996, a once-daily oral small-molecule oral GLP-1 receptor agonist, in Phase I, for treating obesity in patients with and without Type 2 diabetes, as well as two injectable clinical drug candidates: CT-388, a once-weekly subcutaneous injectable in Phase II, for treating obesity in patients with and without Type 2 diabetes, and CT-868, a once-daily subcutaneous injectable, in Phase II, for treating Type 1 diabetes patients with overweight or obesity

eGFR: estimated glomerular filtration rate, CRRT: continuous renal replacement therapy, SBP: systolic blood pressure, pro-ANP: pro-atrial natriuretic peptide, UACR: urinary albumin to creatinine ratio, CKD: chronic kidney disease

doi: 10.1007/s13679-023-00536-x

By six months, the participants had lost 12.7% of their body weight on average

their road to diagnosis